Delivery systems for astaxanthin: A review on approaches for in situ dosage in the treatment of inflammation associated diseases.

Autor: Rivera-Hernández G; Laboratorio de Farmacología Molecular, Departamento de Ciencia y Tecnología, Universidad Nacional de Quilmes, Bernal, Argentina; Institute of Biomaterials, Department of Materials Science and Engineering, University of Erlangen-Nuremberg, Cauerstrasse 6, Erlangen 91058, Germany; Tecnologico de Monterrey, Escuela de Ingeniería y Ciencias, Monterrey, Mexico., Roether JA; Institute of Polymer Materials, Department of Materials Science and Engineering, University of Erlangen-Nuremberg, Erlangen 91058, Germany., Aquino C; Departamento de ingeniería y ciencias exactas y naturales, Universidad Favaloro, Buenos Aires, Argentina., Boccaccini AR; Institute of Biomaterials, Department of Materials Science and Engineering, University of Erlangen-Nuremberg, Cauerstrasse 6, Erlangen 91058, Germany. Electronic address: aldo.boccaccini@fau.de., Sánchez ML; Laboratorio de Farmacología Molecular, Departamento de Ciencia y Tecnología, Universidad Nacional de Quilmes, Bernal, Argentina; Institute of Biomaterials, Department of Materials Science and Engineering, University of Erlangen-Nuremberg, Cauerstrasse 6, Erlangen 91058, Germany. Electronic address: mirna.sanchez@fau.de.
Jazyk: angličtina
Zdroj: International journal of pharmaceutics [Int J Pharm] 2024 Dec 01; Vol. 669, pp. 125017. Date of Electronic Publication: 2024 Dec 01.
DOI: 10.1016/j.ijpharm.2024.125017
Abstrakt: Astaxanthin is a red-orange keto-carotenoid exhibiting antioxidant activity. AST is mainly used in the cosmetic, food, and healthcare industries. Nevertheless, because of its anti-inflammatory effects and immune modulation activity, AST use in pharmacology has been proposed as an alternative for treating neurodegenerative disorders, inflammatory bowel disease, arthritis, atherosclerosis, or diabetic foot ulcers, among others. However, before an AST clinical implementation, it is still necessary to solve challenges related to the use of AST, such as lack of solubility, poor bioavailability, and sensitivity to light, oxygen, and temperature. For that reason, the development of several biomaterials to encapsulate, protect, and dosage AST has been proposed in recent years. This review discusses the use of liposomes, hydrogels, and polymer micro and nanoparticles as vehicles for AST release based on available literature. Additionally, an analysis of released, encapsulated, and effective AST doses is presented, as well as the regulatory landscape of different delivery systems to reveal details of AST delivery, which should inform future strategies for implementing AST in the clinic.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: